MA-BATTERY-VENTURES
26.3.2024 12:01:26 CET | Business Wire | Press release
Battery Ventures, a global, technology-focused investment firm, today announced a significant investment in Mobius Institute (“Mobius”), a company that specializes in reliability improvement, conditioning-monitoring, and precision-maintenance training and certification.
Mobius delivers its training via public, in-plant, and online training programs and has trained more than 70,000 professionals from 180 countries since 2005. In addition to training, a related entity to the company, Mobius Institute Board of Certification, is an ISO/IEC 17024 and ISO 18436-accredited certification body that provides globally recognized certification to reliability professionals, vibration analysts, ultrasound analysts, thermal imaging, and lubrication specialists worldwide.
Mobius Institute is seen as an authority in the industrial asset-reliability space, which is growing in importance as companies transition to predictive and data-based maintenance regimes to operate more efficiently and meet new sustainability targets. Via its network of training partners, Mobius has trained maintenance and reliability professionals across a wide range of industries with students from Pfizer, Rio Tinto, Abbott, Abbvie, Ford, Coca-Cola, Samsung, ABB, Cargill, Nestle, Siemens, Dow, Amazon, Bayer, Mercedes-Benz, NASA, and Hyundai, among others.
Jason Tranter, the co-founder of Mobius, said he hoped the partnership with Battery will help his company scale to a new level. “My wife, Georgie, and I started the business in our house in 1999 with the goal of making vibration analysis and condition monitoring understandable. We never imagined Mobius Institute growing to this scale with almost 10,000 students trained last year alone,” he said. “Having developed a relationship with Battery over the past several years, I am excited to see Mobius continue to grow under Battery’s ownership as the starting point of a new platform.”
As part of the transaction, Tranter will serve as a technical advisor to Mobius.
Battery’s goal with the transaction is to create a large, innovative, asset-reliability and industrial-services player; the firm expects to build upon Mobius’ strength in asset reliability while expanding the portfolio into the broader market for industrial training, certification, and specialized products & services.
As part of this initiative, Marcus Pillion joins the company as Group CEO to drive M&A and continued organic growth, as well as to oversee integration efforts. Pillion joins Mobius after serving most recently as the CEO of Des-Case before its acquisition by Timken (NYSE: TKR) in 2023. Prior to Des-Case, Pillion had previous executive experience across several asset-reliability and condition-monitoring businesses including TRITEC Performance Solutions, Colfax Fluid Handling, EagleBurgmann, SKF and John Crane.
“I am excited to join forces with Battery, a seasoned industrial-technology investor with extensive experience creating platforms through global M&A,” said Pillion. “Having used Mobius Institute training across all of the companies I previously worked for, I am excited to build upon the global brand Mobius has created as we enter into the next phase of its growth trajectory.”
“We are thrilled to partner with Mobius and its exceptional staff as we pursue the next phase of growth for the business,” said Zack Smotherman, a Battery general partner. “Having followed the asset-reliability and condition-monitoring market for many years, we’ve observed an accelerating trend in predictive maintenance and believe we are still in the early innings of this movement as many industries increasingly adopt these solutions.”
Added Battery Principal Justin Rosner: “We are grateful to Jason for the opportunity to partner with Mobius and excited about the journey ahead as we look to leverage Mobius’s global reputation to improve asset reliability across many industries in the years to come.”
About Mobius Institute
Mobius Institute is a worldwide provider of reliability improvement, condition monitoring, and precision maintenance education to industrial plant managers, reliability engineers, and condition monitoring specialists, allowing plants to be successful in implementing reliability improvement and condition monitoring programs. Mobius delivers its training via public, in-person / onsite, and online education programs with a key advantage being its unique training style that uses innovative 3D animations and software simulations, making complex topics easier to understand. Mobius has trained and certified more than 70,000 industrial professionals from 180 countries since 2005 with thousands more engaged through distance learning programs and Mobius’ online community MOBIUS CONNECT. Learn more at https://www.mobiusinstitute.com/about-mobius-institute/.
About Battery
Battery partners with exceptional founders and management teams developing category-defining businesses in markets including software and services, enterprise infrastructure, consumer tech, healthcare IT and industrial technology and life-science tools. Founded in 1983, the firm backs companies at all stages, ranging from seed and early to growth and buyout, and invests globally from offices in Boston, San Francisco, Menlo Park, New York, London, and Tel Aviv. Follow the firm on X @BatteryVentures, visit our website at www.battery.com and find a full list of Battery's portfolio companies here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240326724392/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom